Biotech

All Articles

Ascendis' dwarfism medication hits in period 3, intimidates BioMarin

.Ascendis Pharma has emerged as a possible hazard to BioMarin's Voxzogo, mentioning phase 3 growth a...

Despite ph. 3 skip, Alkeus observes course in advance for eye condition asset

.Though Alkeus Pharmaceuticals' dental eye health condition possession fell short to dramatically le...

Kairos goes public along with $6M IPO to money tests of cancer medicine

.Along with a triad of biotechs attacking the Nasdaq on Friday, it was actually effortless to skip a...

Vaccine and also Keytruda combination successful in squamous cell cancer

.Invulnerable gate inhibitors are the superheroes of cancer therapy. Medicines like Bristol Myers Sq...

Cue Biopharma queues up J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our roundup of substantial management hirings, shootings ...

Regeneron's Opdualag opponent presents 57% response cost

.Regeneron is actually back along with long-lasting consequence for its own LAG-3 inhibitor and PD-1...

AstraZeneca posts data on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has discussed an early check out the performance of its own internal antibody-drug conj...

iTeos- GSK's TIGIT superstar reveals significant remodeling

.After introducing a stage 3 launch based on positive midstage results, iTeos and also GSK are lastl...

More collective FDA can easily accelerate rare condition R&ampD: file

.The FDA ought to be a lot more available as well as joint to release a surge in commendations of un...

Zenas, MBX, Bicara scalp to Nasdaq in warm time for biotech IPOs

.It is actually an extraordinarily busy Friday for biotech IPOs, along with Zenas BioPharma, MBX and...